Selective targeting of the ␣5-subunit of GABAA receptors relaxes airway smooth muscle and inhibits cellular calcium handling. Am J Physiol Lung Cell Mol Physiol 308: L931-L942, 2015. First published February 6, 2015 doi:10.1152/ajplung.00107.2014The clinical need for novel bronchodilators for the treatment of bronchoconstrictive diseases remains a major medical issue. Modulation of airway smooth muscle (ASM) chloride via GABA A receptor activation to achieve relaxation of precontracted ASM represents a potentially beneficial therapeutic option. Since human ASM GABAA receptors express only the ␣4-and ␣5-subunits, there is an opportunity to selectively target ASM GABAA receptors to improve drug efficacy and minimize side effects. Recently, a novel compound (R)-
]i) regulation. Immunohistochemical staining localized the GABAA ␣5-subunit to human ASM. The selective GABAA ␣5 ligand SH-053-2=F-R-CH3 relaxes precontracted intact ASM; increases GABA-activated chloride currents in human ASM cells in voltage-clamp electrophysiology studies; and attenuates bradykinin-induced increases in [Ca 2ϩ ]i, store-operated Ca 2ϩ entry, and methacholine-induced Ca 2ϩ oscillations in peripheral murine lung slices. In conclusion, selective subunit targeting of endogenous ␣5-subunit containing GABAA receptors on ASM may represent a novel therapeutic option to treat severe bronchospasm.
GABAA ␣5-subunit; SH-053-2=F-R-CH3; airway relaxation DESPITE A PRESSING CLINICAL need for novel bronchodilators in the treatment of asthma and other bronchoconstrictive diseases, only three drug classes are currently in clinical use as acute bronchodilators in the United States (methylxanthines, anticholinergics, and ␤-adrenoceptor agonists) (6) . An emerging novel pathway to achieve bronchodilation involves modulating airway smooth muscle (ASM) chloride conductance via GABA A receptors to achieve relaxation of human precontracted ASM (15) . Although there is legitimate concern that widespread activation of all GABA A receptors may lead to undesirable side effects (sedation, hypnosis, etc.), we have shown that human ASM cells express a limited repertoire of GABA A receptor subunits, with the ␣4-and ␣5-subunits the only ␣-subunits expressed, thereby allowing for potential selective pharmacological tissue specific receptor targeting to minimize side effects (18, 33) . Inhaled delivery of these selective compounds may also serve to obviate concerns of systemic effects. Concern regarding nonselective GABA A receptor activation is not limited to the airway. GABA A receptor ligands active in the central nervous system (CNS) can have many effects including anxiolytic, sedative, hypnotic, amnesic, anticonvulsant, and muscle relaxant effects. This motivated a search for benzodiazepine (BDZ) ligands that discriminate among the ␣-subunits of GABA A receptors (41, 42) .
A novel approach to achieve this goal was developed by Cook and coworkers in the 1980s (1, 25) that employed a pharmacophore/receptor model based on the binding affinity of rigid ligands to BDZ/GABA A receptor sites (8) . From this series of receptor models for ␣ 1-6 ␤3␥2 subtypes a robust pharmacophore for ␣5-subtype selective ligands emerged resulting in the synthesis of a novel ␣5␤3␥2 partial agonist modulator: (R)-ethyl 8-ethynyl-6-(2-fluorophenyl)-4-methyl-4H-benzo[f]imidazo [1,5-a] [1, 4] diazepine-3-carboxylate (or SH-053-2=-F-R-CH 3 ) (10) . Given that ␣4-and ␣5-subunit-containing GABA A receptors are known to be present on ASM cells, it was of interest to examine the effects of this ␣5 BDZ/GABAergic subtype-selective agonist on ASM function and cellular signaling.
To assess this we performed immunohistochemistry to ascertain whether GABA A ␣5-subunits colocalized with smooth muscle ␣-actin in ASM intact sections from human upper airways and then questioned whether targeted activation of the restricted ␣5-subunit containing GABA A receptors on ASM cells would also elicit electrophysiological changes in ASM cells consistent with GABA A activation and relaxation of ASM.
The activation of GABA A receptors on ASM has been shown to elicit Cl Ϫ conductance and membrane potential changes (18) ; the impact of these changes on known mechanisms relating to modulation of ASM tone has not been fully investigated. Since changes in membrane potential are known to affect ASM Ca 2ϩ handling (39) and cytosolic Cl Ϫ concentration ([Cl Ϫ ]) has been implicated in attenuating sarcoplasmic Ca 2ϩ flux (21, 23) , we questioned whether activation of ␣5-subunit-containing GABA A receptors on ASM could modulate intracellular calcium concentration ([Ca 2ϩ ] i ) and mediate relaxation of intact ASM.
MATERIALS AND METHODS

Reagents
Indomethacin, N-vanillylnonanamide (capsaicin analog), pyrilamine, acetylcholine, bradykinin, and gabazine were obtained from Sigma (St. Louis, MO). Tetrodotoxin was obtained from Calbiochem (San Diego, CA). SH-053-2=F-R-CH3 was synthesized at the Depart-ment of Chemistry and Biochemistry, University of Wisconsin, Milwaukee (42) .
Immunohistochemistry of Human ASM for GABA A Receptor
␣5-Subunit Protein Expression
All human airway tissue protocols were reviewed by Columbia University Institutional board and were deemed not human subjects research under 45 CFR 46. Human tracheal tissue was obtained from discarded airway from healthy lung donors during transplantation surgery at Columbia University. The trachea and first generation bronchi of the airway were processed for immediate fixation in 4% paraformaldehyde (4°C overnight), then incubated in 30% sucrose in PBS at 4°C for an additional 24 h prior to processing for cryostat sectioning (6 m). The sections were washed in PBS, incubated with 0.1% Triton X-100 for 10 min, blocked with 15% goat serum, and then incubated overnight at 4°C in primary antisera. The primary antibodies used were 1) anti-GABA ␣5 (rabbit, polyclonal; Chemicon no. AB9678, 1:300 dilution in PBS), and 2) anti-␣-smooth muscle actin (mouse, monoclonal; Sigma-Aldrich, no. A2547, 1:10,000 dilution in PBS). The secondary antibodies consisted of FITC-conjugated goat antirabbit IgG (1:400 dilution) and Alexa Fluor 594 goat anti-mouse IgG (1:400 dilution; Invitrogen) incubated for 1 h. Nuclear staining was performed with mounting medium premixed with DAPI stain (Vector Laboratories, no. H-1500). Negative controls omitted all primary antibodies but included secondary staining and nuclear staining steps. All the immunofluorescence experiments were repeated on at least three independent samples. Samples were viewed under confocal microscopy (Nikon A1 Eclipse) and images were acquired with NIS software version 4.10.
Force Measurements in Human ASM Strips
Human ASM strips were dissected from trachea and mainstem bronchi and epithelium was removed under a dissecting microscope. Strips were suspended at 1.5 g resting tension in Krebs-Henseleit (KH) buffer as previously described (17) . Trachea and bronchi were obtained from surgical discards from healthy donor lungs incidental to lung transplant surgery, and studies were deemed not human subjects research after review by Columbia University's Institutional Review Board. KH buffer contained (in mM) 118 NaCl, 5.6 KCl, 0.5 CaCl 2, 0.24 MgSO4, 1.3 NaH2PO4, 25 NaHCO3, and 5.6 glucose, pH 7.4. Indomethacin (10 M) was added to the buffer to block endogenous release of prostanoids. Strips were allowed to equilibrate for 1 h with KH buffer exchanges every 15 min. Strips underwent contractile challenges with acetylcholine (100 nM-100 M) for three cycles with extensive buffer exchanges and resetting of resting tension to 1.5 g between cycles. Tetrodotoxin (1 M), pyrilamine (10 M), and MK501 (10 M) were then added to the buffer to eliminate potentially confounding effects of neural activation, histamine release, or leukotriene release from other cell types (neurons, mast cells) present in the ASM strip preparation during muscle force studies. ASM strips were then contracted with an EC 50 concentration of acetylcholine, and, after establishment of a stable plateau of muscle force (typically ϳ30 min), 10 nM of isoproterenol was added with or without 50 M SH-053-2=F-R-CH 3 or vehicle (0.2% ethanol). The magnitude of remaining muscle force was measured 15 min after the addition of isoproterenol Ϯ SH-053-2=F-R-CH 3 and expressed as a percentage of the initial acetylcholine-induced force.
Force Measurements in Guinea Pig Tracheal Rings
All animal protocols were approved by the Columbia University Animal Care and Use Committee. Male Hartley guinea pigs (ϳ400 g) were anesthetized with intraperitoneal pentobarbital (100 mg/kg). Trachea were removed and dissected under a dissecting microscope into closed rings comprised of two cartilaginous segments. Epithelium was removed by gentle abrasion of the tracheal lumen with cotton. This method has been confirmed by histology to completely remove the epithelial layer without damaging the underlying smooth muscle layer. Tissues were placed into cold KH buffer containing 10 M indomethacin as above.
Closed GP tracheal rings were suspended in organ baths as previously described (46) . Briefly, tissues were hung in a water-jacketed (37°C) 2-ml organ bath (Radnoti Glass Technology, Monrovia, CA) and attached to a Grass FT03 force transducer (Grass Telefactor, West Warwick, RI) coupled to a computer via BioPac hardware and Acqknowledge 7.3.3 software (Biopac Systems, Goleta, CA). KH buffer was continuously bubbled with 95% oxygen and 5% carbon dioxide and tissues were allowed to equilibrate at 1 g isotonic force for 1 h with fresh KH buffer changes every 15 min.
Following equilibration, the capsaicin analog N-vanillylnonanamide (10 M final) was added to the organ baths to first activate and then deplete nonadrenergic, noncholinergic nerves. After N-vanillylnonanamide-induced force had returned to baseline (ϳ50 min), the tracheal rings were washed and then subjected to two cycles of increasing cumulative concentrations of acetylcholine (0.1 M to 0.1 mM) to determine the EC 50 concentrations of acetylcholine required for each individual ring. To avoid bias between treatment groups, tissues were contracted by using acetylcholine at the individually calculated EC 50 value for each tissue, and tissues with similar Emax values were randomly assigned to treatments within individual experiments. To remove confounding effects of other procontractile pathways, each bath received a complement of antagonists 20 min prior to subsequent contractile challenge. The antagonists included pyrilamine (10 M; H 1 histamine receptor antagonist), and tetrodotoxin (1 M; Na ϩ channel blocker to obviate neuronal-mediated cholinergic or C-fiber effects).
Guinea pig (GP) tracheal rings were contracted with either 10 mM tetraethylammonium chloride (TEA) (a nonselective K ϩ channel blocker that induces membrane depolarization, external Ca 2ϩ entry and contraction), or 1 M substance P (a ligand that activates the Gq-coupled neurokinin receptors). Preliminary studies determined that 100 M SH-053-2=F-R-CH 3 induced an ϳ50% relaxation of a substance P-induced contraction in guinea pig tracheal rings. After contractions achieved a steady-state plateau of increased force (typically 30 min), 50 or 100 M SH-053-2=F-R-CH 3 or vehicle (0.2%, 0.4% ethanol) was added and the maintenance of force was measured after 30 min and was expressed as a percent of the initial contractile agonist-induced force.
Human ASM Cell Culture
Human immortalized bronchial smooth muscle cell lines prepared as described (19) were grown to confluence in M199 media (GIBCO) containing 10% fetal bovine serum, 0.25 ng/ml epidermal growth factor, 1 ng/ml fibroblast growth factor, ITS supplement (1 mg/ml insulin, 0.55 mg/ml transferrin, 0.67 g/ml sodium selenium), and antibiotics (100 units/ml penicillin G sodium, 100 g/ml streptomycin sulfate, 0.25 g/ml amphotericin B) in a humidified atmosphere of 5% CO 2/95% air at 37°C. Twenty-four hours prior to studies, cells were fed with fresh media.
Electrophysiology of Human ASM Cells
To investigate whether targeted activation of ␣5-subunit-containing GABAA receptors induces electrophysiological changes in human ASM cells, we measured the effect of SH-053-2=F-R-CH3 on membrane currents. On the day of the assay, immortalized human ASM cells were released from collagen-coated plates with collagenase type IV (Sigma C5138, 500 units/ml), centrifuged at 300 g, resuspended in SmBM2 medium (Lonza), and transferred into collagen-treated glass bottom 1-cm Petri dishes. Cells were then incubated at 37°C in 5% CO 2 95% air for 3-4 h, allowing for reattachment of cells. Following generation of membrane seals (40 -120 M⍀), whole cell configuration was used for current recordings under voltage (holding potential Ϫ60 mV) conditions. To determine a current-voltage (I-V) relationship, voltage was stepped from Ϫ40 to 100 mV in 10 mV increments in the absence and presence of SH-053-2=F-R-CH 3. Studies were performed with a 2-kHz Bessel filter, recording at 10 kHz with use of an Axopatch 200b amplifier (Axon Instruments, Foster City, CA). Perfusion for drug additions were made with the ALA VM-8, 8-chamber pressure-driven drug application system. Electrodes were pulled with a P-97 micropipette puller from 1. To determine whether SH-053-2=F-R-CH 3 evoked-currents are GABA A receptor specific and do not represent "leak" currents, we also performed additional electrophysiology studies utilizing Nanion's Port-a-Patch chip technology (Nanion). Immortalized human ASM cells were released from collagen-coated plates with collagenase type IV (Sigma C5138, 500 units/ml) and centrifuged at 100 g for 2 min. The cell pellet was washed and reconstituted in extracellular recording solution (containing, in mM, 145 NaCl, 5 KCl, 1 MgCl 2, 1.8 CaCl2, 10 TES, pH 7.3, 297 mosM) at a density of 1 ϫ 10 6 cells/ml. Cells were added (5 l) to the recording chamber of a 3-5 M⍀ chip and screened for membrane seals above 450 M⍀ (prior to establishing whole-cell configuration) and a subsequent baseline holding current of less than 2 nA (after establishing whole cell configuration). Cells that met these criteria were first tested for responsiveness to GABA (1 mM) and gabazine (500 M). After confirmation of appropriate currents in the batch of dissociated cells, additional cells that met the above criteria underwent voltage-clamp recordings (VH ϭ Ϫ60 mV) of current evoked by the sequential addition of GABA (1 M) followed by addition of vehicle (0.1% DMSO) or SH-053-2=F-R-CH3 (100 M) and a later addition of gabazine (500 M). All drugs were prepared in the extracellular recording solution. The internal recording solution contained (in mM) 50 CsCl, 10 NaCl, 60 CsF, 20 EGTA, 10 mM TES, pH 7.3, 284 mosM. All patch-clamp recordings were performed at room temperature (20 -24°C). Currents were recorded on an Axopatch 200B amplifier, filtered at 2 kHz, and analyzed with pClamp 10.2 software. Evoked currents were normalized to baseline currents for interexperimental analysis. The data represent recordings from cells isolated on 6 separate days.
Effect of SH-053-2=F-R-CH3 on Agonist-Mediated Increases in Intracellular Calcium
To assess the functional impact of SH-053-2=F-R-CH3 on receptor-Gq coupled Ca 2ϩ handling, Fluo-4 AM assays were performed in immortalized human ASM cells. Three types of Ca 2ϩ assays were performed after pretreatment of cells with SH-053-2=F-R-CH3: 1) the effect on bradykinin-induced increases on [Ca 2ϩ ]i (bradykinin is a ligand for one of several Gq-coupled receptors in ASM); 2) the effect on bradykinin-induced increases in [Ca 2ϩ ]i when Ca 2ϩ was omitted from the external buffer solution; and 3) the effect on store-operated calcium entry (SOCE). Cells were grown to full confluence in blackwalled, clear-bottomed 96-well plates. Medium bathing the cells was removed and the cells were washed with 100 l (per well) of Hanks' balanced salt solution (HBSS) and then loaded with a solution (100 l/well) containing 0.05% Pluronic F-127, 2.5 mM probenecid, and 5 M Fluo-4 AM, dissolved in HBSS. The cells were then incubated for 30 min at 37°C with Fluo-4 AM, washed once, and incubated for an additional 30 min at 37°C (95% air, 5% CO2) with HBSS containing 2.5 mM probenecid. Cells were then pretreated for 15 min with 10 M SH-053-2=F-R-CH3, 200 M gabazine, or vehicle (0.1% DMSO) before the addition of 1 M bradykinin by use of the automatic injection feature of the FlexStation 3 microplate reader (Molecular Devices, Sunnyvale, CA) during continuous fluorescent measurements. The cells were excited at 488 nm every 5 s, and emission data were continuously collected at 516 nm. Real-time changes in intracellular Ca 2ϩ are reported as RFU (relative fluorescence units). Readings from at least three wells per treatment were collected and averaged for each n value.
Effect of SH-053-2=F-R-CH3 on Store-Operated Calcium Entry
To determine the effect of SH-053-2=F-R-CH3 on ASM SOCE, cells were loaded with Fura-2 AM calcium indicator (2.5 M; 100 l per well; Molecular Probes, Eugene, OR) for 45 min in HBSS. Following loading, the cells were washed and incubated at 37°C in Ca 2ϩ -free HBSS with drug pretreatments for 15 min (100 M SH-053-2=F-R-CH3; 100 M gabazine; SH-053-2=F-R-CH3 plus gabazine; 10 M SKF 96365; or 0.2% ethanol vehicle). To passively deplete the sarcoplasmic reticulum (SR) of Ca 2ϩ , the cells were then treated with the sarco/endoplasmic reticulum Ca 2ϩ -ATPase (SERCA) inhibitor thapsigargin (1 M) for 11 min prior to reintroduction of external Ca 2ϩ (2.5 mM). Fura-2 AM fluorescent signal (excitation 340/380 nm and emission 510 nm) was measured continuously by use of a Flex Station 3 plate reader (Molecular Devices, Sunnyvale, CA). Peak signal following Ca 2ϩ reintroduction was normalized to the thapsigargin-induced response and presented as fraction of vehicle, as reported previously (44) .
Effect of SH-053-2=F-R-CH3 on Methacholine-Mediated Contraction and Calcium Oscillations Measured in Peripheral Murine Lung Slices
Preparation of lung slices. These studies were reviewed and approved by the Institutional Animal Care and Use Committee of the Texas Tech University Health Sciences Center (IACUC protocol no. 07069). Mouse lung slices were prepared as previously described (5, 34) . Briefly, male C3H mice (8 -12 wk) were killed with pentobarbital (40 mg/kg ip) and the chest cavity was opened to allow for cannulation of the trachea. The lungs were inflated with 1.4 ml of 2% agarose in HBSS, followed by ϳ0.2 ml of air. The agarose was gelled by cooling the lungs with a cotton ball soaked in ice-cold HBSS and maintaining the mouse body at 4°C for 20 min; following removal, the lungs and heart were held in ice-cold HBSS for 15 min. Lung lobes were transferred to the specimen syringe tube of a tissue slicer (Compresstome VF-300; Precisionary Instruments). The lung lobe was embedded first into ϳ1 ml of 2% agarose and then fully covered with 6% gelatin, after which the block was cut into serial sections of 140 m. Lung slices containing small terminal airways were incubated in low-glucose Dulbecco's modified Eagle's medium supplemented with 1ϫ antibiotic solution containing L-glutamine, penicillin, and streptomycin (Invitrogen) at 37°C and 10% CO 2 in a cell culture incubator for up to 48 h. Lung slices containing airways with a lumen diameter of 100 -300 m, completely lined by active ciliated epithelial cells, and fully attached to the surrounding lung parenchyma were used for experiments.
Measurement of airway contraction and [Ca 2ϩ ]i in lung slices. Measurements of changes in small-airway cross-sectional lumen area (lumen area hereafter) and the fluorescent measurements of [Ca 2ϩ ]i in ASM cells were performed as previously described (34) . Briefly, lung slices were mounted in a custom-made perfusion chamber and airways were visualized by use of a ϫ10 objective. Digital images (640 ϫ 488 pixels) were recorded in time lapse (0.5 Hz) by use of a charge-coupled device camera (KP-M1A; Hitachi), frame grabber (Picolo; Euresys), and image-acquisition software (Video Savant; IO Industries). The lumen area was normalized to the area before stimulation. In some experiments lung slices were loaded with Oregon green 488 BAPTA-1 acetoxymethyl ester (Invitrogen) for the intracellular imaging of Ca 2ϩ as previously described (34) . Changes in fluorescence intensity were analyzed by selecting regions of interest (ROI) ranging from 25 to 49 square pixels. Average fluorescence intensities of an ROI were obtained, frame-by-frame, by using a custom-written script designed to track the ROI within a smooth muscle cell (as it moves due to airway contraction/movement). Final fluorescence values were expressed as a fluorescence ratio (F/F 0) normalized to the initial fluorescence (F0). All experiments were performed at room temperature.
Statistical Analysis
Each experimental procedure included internal controls. Where appropriate, we employed repeated measures in a one-way ANOVA using Bonferroni posttest comparisons. In cases where only two experimental groups were compared, a two-tailed Student's t-test was employed. Data are presented as means Ϯ SE; P Ͻ 0.05 in all cases was considered significant.
RESULTS
The GABA A Receptor ␣5-Subunit Is Expressed in ASM from Human Trachea ASM dissected from the posterior wall of human tracheas demonstrated extensive immunoreactivity for the GABA A receptor ␣5-subunit (Fig. 1 , A and C) that colocalized with immunoreactivity for smooth muscle specific ␣-actin (Fig. 1, B and C). Nonspecific staining was not detected when the primary antibodies were omitted (Fig. 1D) .
A Ligand for GABA A Receptors Containing the ␣5-Subunit Augments ␤-Adrenoceptor Agonist-Mediated Relaxation in Human ASM
We also determined the ability of a ligand directed against GABA A receptors containing the ␣5-subunit to augment ␤-adrenoceptor agonist-mediated relaxation of precontracted human ASM. This is highly clinically relevant since acute rescue of precontracted ASM during an asthmatic exacerbation is accomplished with ␤-adrenoceptor agonists and cases of asthma refractory to standard ␤-adrenoceptor therapy are not uncommon (36) . The ability of 10 nM isoproterenol to relax a precontracted strip of human ASM (acetylcholine EC 50 ) was significantly enhanced in the presence of SH-053-2=F-R-CH 3 (50 M) compared with vehicle control (Fig. 2A) , (n ϭ 8/group P Ͻ 0.01).
A Ligand for GABA A Receptors Containing the ␣5-Subunit Directly Relaxes Depolarization-or Gq-Coupled-Induced Contractions in Guinea Pig ASM
In addition to augmenting ␤-agonist mediated relaxation, we questioned whether the GABA A ␣5 ligand SH-053-2=F-R-CH 3 could directly relax an established contraction induced by membrane depolarization with TEA as well as from activation of a receptor coupled to Gq. The maintenance of contractile force induced by TEA was directly and significantly relaxed by 50 M SH-053-2=F-R-CH 3 compared with vehicle (Fig. 2, B and C) (n ϭ 5/group, P Ͻ 0.05) and the maintenance of contractile force induced by substance P was directly and significantly relaxed by 100 M SH-053-2=F-R-CH 3 compared with vehicle (Fig. 2, D and E) (n ϭ 4 -5/group, P Ͻ 0.01).
Whole Cell Electrophysiological Recordings of Human ASM Cells Demonstrate That the Selective Ligand for GABA A Receptors Containing ␣5-Subunits Induces a Cl Ϫ Current In Vitro
Having demonstrated functional relaxation of intact ASM from both human and guinea pig under three different contractile paradigms, we next investigated the cell signaling effects of SH-053-2=F-R-CH 3 . Using the whole cell configuration we demonstrate a significant current in human ASM cells upon exposure to 10 M SH-053-2=F-R-CH 3 (⌬Ϫ28 Ϯ 7 pA current) compared with vehicle (⌬Ϫ6 Ϯ 3 pA current; n ϭ 4/group, P Ͻ 0.05) (Fig. 3, A and B) . To confirm that these currents were indeed due to Cl Ϫ flux, we examined the I-V relationship in human ASM cells in the presence and absence of SH-053-2=F-R-CH 3 (10 M) (representative tracing, Fig.  3C ). For these studies, we used intracellular and extracellular solutions that were symmetrical for [Cl Ϫ ]. The predicted chloride equilibrium potential was 0.4 mV and the measured equilibrium potential was 0.73 mV. Additionally, we observed Fig. 1 . Immunohistological characterization of the GABAA receptor ␣5-subunit protein expression in intact human tracheal airway smooth muscle (ASM). Confocal microscopy images employing single, double, and triple immunofluorescence labeling using antibodies directed against GABAA receptor ␣5 subunit (green), ␣-smooth muscle actin (SMA) (red), and/or the nuclear counterstain DAPI (blue). Representative images from native human tracheal ASM are depicted. DAPI and GABAA ␣5-subunit costaining, ␣-SMA alone, triple staining and merging of GABAA ␣5, ␣-SMA, and DAPI nucleus counterstain, with primary antibodies omitted as negative control. . D: representative current tracing utilizing the Port-aPatch single cell recording platform to illustrate GABAA-specific responses. Whole cell recording of a human ASM cell illustrates current changes evoked following the sequential addition of GABA (1 M), SH-053-2=F-R-CH3 (100 M), and then gabazine (500 M). E: graph of compiled current changes evoked by GABA (1 M), SH-053-2=F-R-CH3 (100 M) in the presence of GABA 1 M, and gabazine 500 M in the presence of SH-053-2=F-R-CH3 (100 M) and GABA (1 M). Data from each cell are expressed as normalized values from stable baseline current prior to addition of any drugs (n ϭ 5-7/group, **P Ͻ 0.01, ***P Ͻ 0.001; n.s., not significant).
a change in the slope of the I-V curve with the bath application of 10 M SH-053-2=F-R-CH 3 (Fig. 3C) , indicating that chloride current in these cells was increased in the presence of SH-053-2=F-R-CH 3 .
Automated Port-a-Patch Whole Cell Electrophysiological Recordings of Human ASM Cells also Demonstrate Current Evoked by SH-053-2=F-R-CH 3 Is Reversible by the Classic GABA A Channel Antagonist Gabazine
To confirm that SH-053-2=F-R-CH 3 -mediated electrophysiological responses are GABA A receptor specific, we investigated whether currents induced by SH-053-2=F-R-CH 3 exposure of human ASM cells were attenuated by subsequent treatment with gabazine (Fig. 3, D and E) . Compared with baseline current, we observed no significant change in current in human ASM cells upon exposure to 1 M GABA (6 Ϯ 2 ⌬pA, n ϭ 5, P Ͼ 0.05) or following the subsequent administration of DMSO (0.1%) vehicle (9 Ϯ 5 ⌬pA; n ϭ 5, P Ͼ 0.05). However, we did observe a significant inward current when SH-053-2=F-R-CH 3 (100 M) was applied subsequent to receiving 1 M GABA (195 Ϯ 44 ⌬pA; n ϭ 7, vs. 8 Ϯ 5 ⌬pA; n ϭ 7, respectively; P Ͻ 0.001). We also observed a significant reversal of current when gabazine (500 M) was subsequently applied to cells that received SH-053-2=F-R-CH 3 (39 Ϯ 9 ⌬pA; n ϭ 7, P Ͻ 0.01) compared with the current generated by SH-053-2=F-R-CH 3 (194.8 Ϯ 43.5 ⌬pA; n ϭ 7). Gabazineinduced change in current was not significantly different compared with current obtained from the preceding 1 M GABA treatment. A representative tracing of the current induced by SH-053-2=F-R-CH 3 and its subsequent attenuation by a GABA A -specific antagonist (gabazine) is shown in Fig. 3D .
SH-053-2=F-R-CH 3 Attenuates Contractile Agonist Mediated Rise in [Ca 2ϩ ] i That Is Significantly Attenuated by the GABA A Antagonist Gabazine
We next investigated the effect of SH-053-2=F-R-CH 3 on Ca 2ϩ regulation under three paradigms: increases in bradykinin-induced [Ca 2ϩ ] i in the presence and absence of extracellular Ca 2ϩ , and SOCE. Pretreatment with 10 M SH-053-2=F-R-CH 3 significantly attenuated the increase in [Ca 2ϩ ] i induced by 1 M bradykinin, and this effect of SH-053-2=F-R-CH 3 was eliminated if the cells were simultaneously pretreated with the GABA A antagonist gabazine (200 M) (Fig. 4, A and B (Fig. 5 , n ϭ 5-8/group, P Ͻ 0.01). This effect of SH-053-2=F-R-CH 3 was reversed by simultaneous pretreatment with the GABA A receptor antagonist gabazine. SKF 96365, a known SOCE inhibitor, served as a positive control for our assay and also led to a significant decrease in Ca 2ϩ influx (Fig. 5 , n ϭ 5-8/group, P Ͻ 0.05).
SH-053-2=F-R-CH 3 Attenuates Methacholine-Induced Peripheral Airway Contractions and Ca 2ϩ Oscillations
Airway lumen area in the peripheral regions of mouse lungs decreased to ϳ35% of the initial resting luminal area upon stimulation with 0.3 M methacholine (MCh) (Fig. 6A) (n ϭ 4 airways, P Ͻ 0.001 compared with baseline). This airway constriction was acutely reversed when SH-053-2=F-R-CH 3 (100 M) was added to the perfusing buffer in the continued presence of 0.3 M MCh, allowing the airways to dilate to ϳ90% of their initial luminal area ( We then measured Ca 2ϩ oscillations induced by MCh in ASM cells of mouse lung slice while simultaneously measuring luminal area (Fig. 6B) . MCh induced Ca 2ϩ oscillations at ϳ14 spikes/min, and these were totally eliminated by the addition of the GABA A receptor ␣5 ligand SH-053-2=F-R-CH 3 (100 M) (Fig. 6B and Supplemental Video S1; Supplemental Material for this article is available on the Journal website) (n ϭ 4 airways, P Ͻ 0.001 comparing MCh to MCh ϩ SH-053-2=F-R-CH 3 ). The induction of Ca 2ϩ oscillations by MCh was accompanied by a reduction in airway luminal area to ϳ40% of the initial luminal area. This airway constriction relaxed with the addition of SH-053-2=F-R-CH 3 and was concomitant with the loss of Ca 2ϩ oscillations.
DISCUSSION
The major findings of this study are that human ASM possesses GABA A receptors with an ␣5-subunit profile that can be pharmacologically targeted by a selective ligand. In intact human ASM the GABA A receptor ␣5-subunit-selective ligand (SH-053-2=F-R-CH 3 ) enhanced ␤-adrenoceptor agonistmediated relaxation. In intact guinea pig ASM the GABA A receptor ␣5-subunit-selective ligand relaxes an established contraction induced by membrane depolarization (TEA) or by activation of a Gq-coupled neurokinin receptor. In isolated human ASM cells this GABA A receptor ␣5-subunit-targeting ligand elicits a Cl Ϫ current, consistent with GABA A receptor activation, and attenuates multiple mechanisms of plasma membrane Ca 2ϩ entry. The expression of only two subtypes of GABA A receptor ␣-subunits in human ASM (only ␣4 and ␣5 are expressed) is an important consideration since these subunits play a key role in determining GABA A receptor localization and pharmacology (20, 37) . The ␣-subunit plays a critical role in ligand (both agonist and allosteric) binding. This is illustrated by the binding of classical 1,4 benzodiazepines at the interface of ␥-and ␣-subunits of ␣1-, ␣2-, ␣3-, and ␣5-subunit-containing GABA A receptors (43) but not at GABA A receptors containing ␣4-or ␣6-subunits (12, 47) . Furthermore, among the active benzodiazepine ␣-subunits (␣1, ␣2, ␣3, or ␣5), there are differential pharmacological profiles such that different ␣-subunits confer varied drug affinities. This has been shown for the nonclassical benzodiazepine agonist zolpidem, which demonstrates highest affinity for receptors containing the ␣1-subunit, followed by receptors containing an ␣2-or ␣3-subunit (35), and ␣5-subunit-containing receptors displaying an exceedingly low affinity (2, 38) . These studies laid the foundation for subsequent studies that have established that particular drug effects associated with classical benzodiazepine agonists (se- dation, anxiolysis, ataxia, and amnesia) are ␣-subunit dependent. More specifically, GABA A receptors containing ␣1-subunits are thought to be primarily responsible for the sedative effects of benzodiazepines, whereas ␣2-and ␣3-subunits are implicated in the anxiolytic effects of benzodiazepines (13, 30, 32, 40) . Finally, GABA A receptors containing ␣5-subunits are a relatively minor population in the CNS that may play a role in memory processes, but not in motor or sedation effects (9) . This underlies a secondary potential benefit of drugs targeting ␣5-subunit-containing GABA A receptors, namely that they are devoid of many potentially negative CNS side effects.
As mentioned earlier, pharmacophore receptor models for the ␣1-6␤3␥2 benzodiazepine/GABA A -ergic subtypes were developed in the 1980s and refined in the 1990s. This led to the synthesis of a series of chiral R-and S-isomers of earlier imidazobenzodiazepines that exhibited subtype selectivity at ␣2 and ␣3 subtypes. However, as reported in Fischer et al. (14) , the in vitro binding affinity of SH-053-2=F-R-CH 3 was clearly higher at ␣5␤3␥2 subtypes with very little affinity at ␣1, ␣2, or ␣3 subtypes [K i values: ␣1␤3␥2 (759.1), ␣2 (948.2), ␣3 (768.8), and ␣5 (95.2) nM]. The C-6 pendent phenyl ring of SH-053-2=F-R-CH 3 is incompatible with binding at ␣4 and ␣6 diazepam-insensitive benzodiazepine GABA receptors. Moreover, the efficacy in oocytes (% control currents) at ␣5-subtypes was higher than at the other three subtypes (14) . In addition, the in vivo data for SH-053-2=F-R-CH 3 compared with diazepam in primates clearly show that SH-053-2=F-R-CH 3 is not sedating (␣1 activity is low) and that the anxiolytic activity of this R-CH 3 isomer is either very weak or nonexistent. This indicates that this R-CH 3 isomer does not activate ␣2 or ␣3 BDZ receptor subtypes to any appreciable extent in this primate conflict model.
With the targeted development of allosteric GABA A receptor ligands with selectivity for GABA A receptors containing ␣5-subunits, it is particularly fortuitous that the repertoire of GABA A receptor ␣-subunits on human ASM is restricted to only the ␣4-and ␣5-subunits. Indeed, we have previously shown that a ligand selective for the ␣4-subunit (CMD-45) as well as gaboxadol, a well-known ligand with ␣4 selectivity, regulate ASM tone (18) . Thus a goal of the present study was to determine whether ␣5 targeting could also realize these beneficial effects of ASM contractile tone. We also sought to determine whether [Ca 2ϩ ] i , a critical regulator of ASM tone, was regulated by GABA A receptor ␣5-subunit-targeting ligands.
One component of asthma is the enhanced mass and contraction of ASM and drugs used for the acute relief of an asthmatic exacerbation target acute relaxation of ASM. The leading pharmaceutical drug class for this critical clinical therapy is ␤-adrenoceptor agonists, and in the present study we demonstrate that SH-053-2=F-R-CH 3 augmented the relaxation effect of a ␤-agonist in intact human ASM. These findings suggest a clinically relevant role for targeting ␣5-subunitcontaining GABA A receptors in the acute relaxation of human ASM.
We next demonstrated that SH-053-2=F-R-CH 3 alone could relax an established contraction by a depolarizing stimulus (TEA) or a G q -coupled ligand (substance P) in guinea pig ASM. These results also highlight an important mechanistic fact regarding SH-053-2=F-R-CH 3 mediated relaxation, namely that GABA A receptor mediated-relaxation does not involve K ϩ channels. So, whereas ␤-adrenoceptor relaxation does involve a component of PKA-mediated large conductance K Ca channel activation (and SH-053-2=F-R-CH 3 mediated GABA A activation does augment isoproterenol relaxation), SH-053-2=F-R-CH 3 's capacity to relax a TEA contraction (achieved by K ϩ channel blockade) suggests complementary mechanisms of relaxation, not mechanistic overlap at the same receptor or K ϩ channel. The relaxation of SH-053-2=F-R-CH 3 in these ex vivo muscle force studies in human and guinea pig ASM under several different contraction/relaxation paradigms led us to investigate accompanying cellular events in cultured human ASM cells.
Whole cell electrophysiology experiments demonstrated a current with a reversal potential at the predicted voltage for chloride, and this chloride current was enhanced in the presence of SH-053-2=F-R-CH 3 and blocked by the GABA A receptor antagonist gabazine. A chloride current at the plasma membrane would change membrane potential of the plasma membrane, which in turn may modulate numerous Ca 2ϩ entry pathways. Although Ca 2ϩ control in an ASM cell is complex, involving multiple channels, exchangers, and pumps on both the plasma membrane and intracellular organelles, a component of intracellular Ca 2ϩ handling is regulated by membrane potential. Indeed, in addition to voltage-gated Ca 2ϩ channels (19) , Na ϩ /Ca 2ϩ exchangers (22, 31) , nonselective cation channels of the TRP family (7), and perhaps even SOCE are all influenced by membrane potential (29 influx during bradykinin treatment. This was supported by additional experiments in which SH-053-2=F-R-CH 3 was without effect in the absence of extracellular Ca 2ϩ . These findings suggest that SH-053-2=F-R-CH 3 is blocking the component of bradykinin-induced [Ca 2ϩ ] i that arises from extracellular sources, which is likely a complex acute response involving Ca 2ϩ exchangers and SOCE to refill the cytosol and SR. To further investigate whether SH-053-2=F-R-CH 3 also modulates Ca 2ϩ handling relevant to the maintenance phase of a contraction, we performed additional studies examining the role of SH-053-2=F-R-CH 3 -mediated GABA A activation on SOCE and calcium oscillations in airway slices.
Following the release of SR Ca 2ϩ in ASM, an influx of extracellular Ca 2ϩ occurs to refill the SR store, a process referred to as SOCE (27) . SH-053-2=F-R-CH 3 led to a significant decrease in SOCE via a GABA A receptor-specific effect since it is reversed by the GABA A receptor antagonist gabazine.
In ASM, the resting membrane potential is thought to be approximately Ϫ60 mV and the reversal potential of chloride is thought to be approximately Ϫ20 to Ϫ30 mV (28) . Thus GABA A agonists would lead to a depolarization of ASM resting membrane potential. In lymphocytes, a cell type in which SR store-operated Ca 2ϩ influx has been extensively studied owing to its key role in T cell receptor-mediated cellular activation and proliferation, membrane depolarization is known to greatly inhibit store-operated Ca 2ϩ influx, likely by reducing the driving force for Ca 2ϩ entry through the STIM-ORAI complex (3, 24) . Since GABA A activation is predicted to depolarize ASM resting membrane potential, a similar effect may be occurring in this in vitro SOCE assay with ASM.
However, in contrast to effects at membrane potentialcontracted ASM, after Gq-coupled receptor activation for example, the membrane potential is expected to be depolarized. Under these conditions, GABA A activation would be expected to lead to a relative hyperpolarization, which would increase the electrostatic driving force for extracellular Ca 2ϩ entry. This would seem at odds with the ability of GABA A agonists to relax precontracted ASM in organ bath preparations. However, under these conditions, this relative hyperpolarization may inhibit capacitive Ca 2ϩ influx via voltage sensitive L-type Ca 2ϩ channels and/or the reverse mode of the Ca 2ϩ -sodium exchanger, which have been shown to be key in ASM for maintaining intracellular Ca 2ϩ necessary to sustain contraction (22) . Further studies are needed to confirm this hypothesis.
In contrast to the findings presented in the current study with an allosteric agonist of the GABA A chloride channel, our laboratory has also demonstrated that antagonists of another family of chloride channels (calcium-activated chloride channels, TMEM16, or anoctamin) can also mediate ASM relaxation (11, 16, 45) . It may appear surprising that agonism of one type of chloride channel could result in the same physiological effect as antagonism of a different family of chloride channels. These interesting findings were addressed in an editorial focus by Dr. Janssen (26) that presented a number of mechanistic hypotheses to account for seemingly opposing effects of ligand-gated GABA A channels vs. calcium-and voltage-gated calcium-activated chloride channels. These mechanistic differences include an oscillating membrane potential from electrical slow waves, distribution of different types of chloride channels on the plasma membrane vs. intracellular organelles, cytosolic compartmentalization of chloride (as is already known to exist for calcium), and the possibility that intracellular effectors can interact with certain ion channels (or whether chloride itself acts) in certain microdomains to modulate other intracellular contractile effectors. These spatial and temporal mechanisms may be quite different in calcium-activated chloride channels, which are regulated by both calcium and voltage (4), compared with GABA A chloride channels, which are ligand gated.
In summary, we present the following evidence: 1) that targeting of ␣5 GABA A ␣-subunits in ASM produces characteristic electrophysiological changes indicative of GABA A receptor activation, 2) that this selective agonist can augment ␤-agonist-mediated relaxation, 3) that GABA A ␣5 receptor activation can directly and spontaneously relax precontracted ASM, and 4) that a component of the mechanism involves an attenuation of Ca 2ϩ handling (as reductions in both agonistinduced external Ca 2ϩ entry and reductions in SOCE in human ASM cells as well as in calcium oscillations in ASM within intact peripheral lung slices). As such, these studies hold promise and potential for improving the armamentarium of pharmacological agents available to treat acute airway bronchoconstriction and suggest a novel role for chloride in the modulation of Ca 2ϩ handing in ASM.
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